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Abstract
In view of the enormous popularity of mass sporting 
events such as half-marathons, the number of patients 
with exertional rhabdomyolysis or exercise-induced 
heat stroke admitted to intensive care units (ICUs) 
has increased over the last decade. Because these 
patients have been reported to be at risk for malignant 
hyperthermia during general anesthesia, the intensive 
care community should bear in mind that the same risk 
of life-threatening rhabdomyolysis is present when these 
patients are admitted to an ICU, and volatile anesthetic 
sedation is chosen as the sedative technique. As illustrated 
by the three case studies we elaborate upon, a thorough 
diagnostic work-up is needed to clarify the subsequent 
risk of strenuous exercise, and the anesthetic exposure 
to volatile agents in these patients and their families. 
Other contraindications for the use of volatile intensive 
care sedation consist of known malignant hyperthermia 
susceptibility, congenital myopathies, Duchenne muscular 
dystrophy, and intracranial hypertension. 
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Intensive care sedation; Inhalational anesthetics; Malignant 
hyperthermia; Congenital myopathies 
World Journal of
Critical Care MedicineW J C C M
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.5492/wjccm.v6.i1.21
World J Crit Care Med  2017 February 4; 6(1): 21-27
ISSN 2220-3141 (online)
© 2017 Baishideng Publishing Group Inc. All rights reserved.
22 February 4, 2017|Volume 6|Issue 1|WJCCM|www.wjgnet.com
Heytens K et al . Heatstroke and volatile anesthetic sedation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Recent research has shown that a substantial 
proportion of patients with exercise-induced heatstroke 
harbor mutations in the ryanodine-receptor one gene 
on Chromosome 19 (RYR1), encoding for the principal 
calcium-release channel in striated muscle. These same 
mutations are known to result in a massively increased 
calcium-conductivity and life-threatening rhabdomyolysis 
when malignant hyperthermia (MH) susceptible patients 
are exposed to volatile anesthetics during general 
anesthesia. In view of this, exposure to volatile anesthetic 
sedation - an emerging trend in intensive care units - 
is contraindicated, not only in patients with known MH 
susceptibility and other congenital myopathies, but also in 
patients admitted because of exertional rhabdomyolysis 
and heatstroke. 
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INTRODUCTION
Exercise-induced rhabdomyolysis (EIR), also known 
as exertional rhabdomyolysis, is a clinical emergency 
characterized by extensive post-exercise muscle necrosis 
and the release of intracellular muscle components into 
the circulation. The diagnosis is confirmed by a significantly 
elevated serum creatine kinase (CK) level and/or the 
presence of myoglobinemia and myoglobinuria. There 
is no definitive pathological CK cut-off, and therefore, 
clinical symptoms such as muscle swelling, myalgia, and 
tenderness occurring with low-intensity exercise, or lasting 
several days longer than expected, are important clinical 
signs.
The most severe end of the clinical spectrum-and one 
of the leading causes of death in young athletes-is known 
as exertional heat stroke (EHS), a syndrome clinically 
defined as a body temperature over 40 ℃, with severe 
rhabdomyolysis and signs of encephalopathy ranging from 
confusion to convulsions or coma. It is often complicated 
by multiorgan failure, including acute renal and hepatic 
failure, and it may result in death if appropriate treatment 
in an intensive care setting is delayed. 
It has been reported for over two decades that a 
significant part of patients with a history of EIR and/or 
heat stroke is at increased risk of developing malignant 
hyperthermia (MH) during general anesthesia[1,2].
MH is well known among anesthetists. It is inherited 
as an autosomal dominant, genetically heterogeneous 
trait that manifests as an acute rhabdomyolysis during 
general anesthesia when susceptible individuals are 
exposed to volatile anesthetics and/or succinylcholine. 
The incidence is generally estimated to be approximately 
1 in 50000 general anesthesias. In the 1970-1980s, 
mortality was over 80%, but now, it is fortunately less 
than 5%[3].
A fulminant MH-crisis is characterized by a com-
bination of clinical and biochemical events: Inappropriate 
hypercapnia and respiratory acidosis, polypnea, tach-
yarrhythmia, rapidly increasing body temperature, 
sweating, generalized muscle rigidity, hemodynamic 
instability, dark urine due to myoglobinuria, significant 
CK-increase (often > 10.000 IU/L), and postoperative 
stiffness and myalgia. Death may result from severe 
hyperkalemia in combination with respiratory and meta-
bolic acidosis, acute renal failure, hyperthermia > 42 ℃, 
disseminated intravascular coagulation and fatal cardiac 
arrhythmias.
Mortality has decreased significantly over the last 
20 years because of our better understanding of the 
syndrome, the use of end-tidal CO2 (ETCO2) monitoring 
resulting in earlier diagnosis, and the availability of the 
antidote dantrolene. 
Treatment consists of the immediate discontinuation 
of volatile anesthetic agents and the administration of 
dantrolene. The surgical procedure should be terminated 
as quickly as possible and if the procedure cannot be 
aborted, the anesthesia technique has to be converted 
to total intravenous anesthesia. Dantrolene should 
be administered as a loading bolus of 2.5 mg/kg Ⅳ. 
Subsequent doses of 1 mg/kg Ⅳ can be repeated up 
to a maximum dose of 10 mg/kg, and are administered 
until the clinical signs (hypercapnia, hyperthermia, rigidity) 
abate. Concomitantly minute volume should be maximized 
to reduce respiratory acidosis. 
Despite adequate treatment, complications still occur 
in 20% of patients. The most common complication is 
renal dysfunction and acute renal failure. The complication 
rate increases to ≥ 30% when 20 or more minutes 
elapse between the first clinical sign and dantrolene 
treatment[4]. 
This life-threatening anesthesia-related complication 
is due to the occurrence of point mutations in the genes 
coding for the calcium-release channel of the sarcoplasmic 
reticulum, e.g., the didyropyridine - ryanodine receptor 
complex, resulting in a disturbed skeletal muscle calcium 
homeostasis. The ryanodine receptor (RYR1 gene on 
Chromosome 19q) contains the actual “calcium pore”. The 
NH2-terminal of this protein forms cytosolic protrusions 
that extend toward, and make contact with, the voltage-
gated dihydropyridine receptor located in the T-tubular 
wall. The corresponding gene for this protein is CACNA1S 
on Chromosome 1. Depolarization of the sarcolemma 
and T-tubule first activates the dihydropyridine receptor 
which in turn activates the ryanodine receptor and opens 
the calcium-channel as such.
As illustrated in Figure 1, the muscle from patients 
harboring RYR1 and/or DHPR mutations upon exposure 
to volatile anesthetics has been shown to exhibit an 
increased calcium-conductivity and massive calcium re-
lease from the SR, in turn resulting in sustained muscle 
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contraction, a catabolic state, and hyperacute muscle 
breakdown[3].
Susceptibility to MH is diagnosed by in in vitro con-
tracture testing (IVCT) in which skeletal muscle fascicles, 
obtained by biopsy, are exposed to incremental concen-
trations of caffeine and halothane in a test bath. The 
muscle contracture obtained in response to the drugs 
is measured, and is, when above a certain threshold, 
indicative of MH susceptibility. The test is considered 
positive [malignant hyperthermia susceptible (MHS)] if 
a contracture of at least 2 mN is obtained at halothane 
concentrations of 2 Vol% or less, and/or a caffeine 
concentration of 2 mmol/L or less. Malignant Hyper-
thermia negative (MHN) patients do not develop a 
significant contracture at these concentrations. The 
European Malignant Hyperthermia Group has standardized 
this test across Europe. The degree of sensitivity and 
specificity is 99% and 93.5% respectively[5]. The invasive 
character of the test however hampers its widespread use 
as a screening instrument. 
Genetically, MH is dominantly inherited. Its estimated 
prevalence is 1 in 3000[3]. Over the years both chromo-
somal and allelic heterogeneity have been demonstrated 
but fortunately, RYR1 mutations can be found in 50% to 
70% of families[3]. Therefore, in an emergency setting, if 
general anesthesia is required in MHS patients, a trigger 
free anesthetic technique - avoiding volatile anesthetic 
agents and/or succinylcholine - is indicated to avoid this 
potentially lethal complication. 
By extension, patients with a history of EIR/EHS are 
at increased risk of developing an MH event, e.g., severe 
life-threatening rhabdomyolysis when they are exposed 
to volatile anesthetic sedation, which is an emerging 
trend in intensive care units (ICUs). Because this fact 
may not be well known enough among non-anesthetist 
intensive care specialists, we report three patients with 
recurrent exertional rhabdomyolysis and/or heat stroke 
to illustrate the complex relationship with MHS, and we 
review the literature on this topic. 
Patient 1
Male, 43 years of age. Reason for investigation: Re-
current episodes of EIR when participating in half-
marathons. During a 2007 half-marathon, he presented 
with an exercise-induced heat stroke (hyperthermia > 
40 ℃). No further clinical details are available. A second 
episode of ER was noticed 1 year later during a 20-km 
run. He developed an epileptic insult before finishing 
the race. At admission, his temperature was 39.8 ℃. 
More convulsions occurred and his Glasgow coma scale 
score dropped to 8/15. Sedation with propofol was 
started, and he was intubated and artificially ventilated. 
Rhabdomyolysis was diagnosed on the basis of a CK level 
of 92.000 IU/L, and acute kidney failure occurred (max 
creatinine level of 3.2 mg/dL), yet with spontaneous 
recovery and without the need for hemodialyis. The 
patient could be weaned from mechanical ventilation 
after 7 d. Further recovery was uneventful. Personal and 
medical history: Wrist fracture reduction under general 
anesthesia, active sportsman (handball and squash for 
years, recent focus on jogging). In between the two 
episodes of hyperthermia, there were no signs of any 
myopathy: No myalgias, no cramps, no weakness, and no 
episodes of cola-colored urines. The family history was 
negative for myopathies, sudden death, or anesthesia-
related complications. His physical examination was 
normal, as well as Holter monitoring and echocardio-
graphy. The resting CK level was 90 IU/L (N < 193 IU/L), 
lactate 0.68 mmol/L (N < 2 mmol/L). The ischemic exercise 
test forearm was normal, ruling out glycogen storage 
disease and myoadenylate deaminase deficiency. The 
EMG only showed non-specific minor myogenic changes. 
A 2009 muscle biopsy of the left M. quadriceps revealed 
a significantly increased number of centrally located 
nuclei. His IVCT was normal, and not indicative of MHS. A 
molecular genetic analysis could not reveal any mutation 
in the carnitine palmitoyl transferase 2 gene (CPTⅡ), or 
RYR1.
Patient 2
Male, 34 years of age. Reason for investigation: Re-
current episodes of EIR during cycling. The first major 
episode occurred during preparation for a cycling event 
in 2010 when he complained of severe cramping pain 
in both thighs, and his CK level was found to be 49.536 
IU/L and myoglobinuria. Renal failure did not develop. 
In 2013, after cycle training for 5-6 h, he complained 
of pronounced muscle weakness with difficulty to walk 
for a few days. This was accompanied by a CK increase 
to 9.222 IU/L. He is an avid amateur cyclist, practicing 
several days a week, most often totaling 400 km/wk, and 
quite regularly participates in a semi-professional tour of 
up to 220 km in one day. Retrospective analysis showed 













Figure 1  Functional implication of RY1/DHPR receptor mutations after 
exposure to volatile anesthetics. The action potential generated in the motor 
endplate is propagated along the sarcolemma and down the T-tubules, to be 
captured by the voltage sensitive dihydropyridine receptor. The depolarization-
induced conformational change in this receptor in turn results in the opening 
of the RYR1 calcium-channel and calcium release from the SR. Mutations in 
the ryanodine-dihydropyridine receptor complex upon exposure to inhalational 
anesthetics lead to a “longer open state” of RYR1, massive calcium release 
from the SR, and eventually widespread muscle breakdown. 
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mainly consisting of myalgia with feeling of stiffness, and 
intermittent myoglobinuria and CK increase. In between 
the crises, there is normal mobility and power, and no 
CK increase. He had not yet been exposed to volatile 
anesthetics. The family history is negative for anesthesia-
related events. His father ran marathons, reporting no 
clinical events. His neurological examination was normal, 
and functional and biochemical tests showed a basal 
CK serum level of 293 U/L, a lactate of 0.8 mmol/L, a 
normal ischemic forearm exercise test and EMG. Muscle 
biopsy of the left M. quadriceps femoris in 2011 showed 
an increased number of fibers with internal nuclei and a 
minor increase of neutral fat drops in some type 1 fibers. 
These were interpreted as unspecific findings. A repeat 
muscle biopsy of the left M. quadriceps femoris in 2014 
again demonstrated findings of mild myopathic disease: 
Increased number of fibers with internal nuclei (25%) but 
also a small number of “cores”, which are zones devoid 
of enzymatic staining. IVCT results: 8 mN contracture 
at 2 Vol% Halothane, 6 mN contracture with 2 mmol/L 
Caffeine, indicative of MHS. Molecular genetic analysis did 
not reveal any mutation in the CPTⅡgene or RYR1.
Patient 3
Male, 56 years of age. Reason for investigation: Recurrent 
myalgia confined to the thigh muscles, described as 
a sensation of severe tension or cramps, sometimes 
unilateral, sometimes bilateral. The type of effort appeared 
not to be related to the complaints: At times a prolonged 
effort did not provoke any myalgia, whereas at other 
times, the pain/cramps started after as short an effort 
of 5-10 min such as descending a staircase. CK values 
measured during an episode of myalgia rose up to 
14.000 IE/L. He is also an amateur cyclist, but complaints 
were only noticed after the age of 40. There was no 
previous exposure to volatile anesthetics, and the family 
history was also negative for anesthesia-related events. 
His son is not active in sports (his daughter is), but until 
now has not mentioned any complaints. His clinical 
examination was normal, but he showed an increase in 
basal CK value of 269-1771 IU/L at diverse occasions, 
lactate was 1.2 mmol/L, and the ischemic forearm test 
was normal. A 2015 muscle biopsy only showed atypical 
myogenic anomalies. The IVCT was abnormal (5 mN 
contracture with 2 mmol/L Caffeine, 14 mN contracture 
with 2 Vol% Halothane), demonstrating MHS. Molecular 
genetic analysis did not reveal a mutation in the CPTⅡ 
gene, but RYR1- mutation analysis demonstrated a base-
pair change in exon 43 (p.N2342S; c.7025A > G). 
DISCUSSION
There is an emerging trend of using inhalational an-
esthetics for ICU sedation[6]. The principle motivation 
is that inhalational anesthetics have an interesting 
pharmacokinetic profile compared with the usual com-
bination of propofol or benzodiazepine with an analgesic 
drug. Several practical advantages have been proposed, 
such as rapid onset and offset of action, low potential for 
accumulation in fat tissue, drug clearance through the 
lungs and therefore independent of liver and/or renal 
function, no tachyphylaxis, an opium sparing effect, 
bronchodilatory properties, and end-organ protective 
properties, such as ischemic preconditioning of the heart, 
although clinical data remain limited on this. 
Until about a decade ago, the technical prerequisites 
for ICU use of volatile anesthetics were not fulfilled, 
and therefore, their use remained confined to the OR. 
Technological advances, however, have greatly sim-
plified the application of inhalational anesthetics for ICU 
sedation. An important milestone was reached in 2005 
with the introduction of a volatile anesthetic reflection 
filter, the anesthetic conserving device (AnaConDaTM, 
Sedana Medical, Uppsala, Sweden), retaining 90% of 
the volatile anesthetic and thereby enormously reducing 
the consumption of volatile anesthetic. Since then, other 
AnaConDaTM competing devices have been produced 
and tested such as the MirusTM (Pall Medical, Dreieich, 
Germany)[7]. Suitable volatile agents are isoflurane, 
sevoflurane, and desflurane. From a drug delivery point 
of view, these technical developments have indeed 
resulted in easy titration to the clinical end-point and 
the possibility of breath-by-breath bedside monitoring. 
A 0.3-0.6 minimal alveolar concentration of sevoflurane 
is most often sufficient in the ICU setting. In view of the 
increased CO2 through the systems’ enlarged dead space 
(100 mL), minute volume usually has to be increased by 
being guided by ETCO2 or blood gas analysis. Desflurane 
is not commonly used in the ICU in view of its boiling 
point of 22.8 ℃, requiring a vaporizer heated to 39 ℃, 
and the higher cost. It can be administered by the 
MirusTM device, not the AnaConDaTM.
Recent studies have indicated that the currently 
available scavenger devices that are based on a silica 
zeolite matrix, adequately adsorb the volatile agents and 
thereby minimize environmental pollution by volatile an-
esthetic agents guaranteeing workplace safety[8].
The question still remains to be answered whether 
volatile anesthetics will really become and stay a player 
in critical care sedation[6]; however, the technique is 
being increasingly used in Europe and North-America. 
A pilot randomized controlled trial is currently being 
set up to evaluate the practicability and dangers related 
to volatile anesthetic agents when used for long-term 
critical care sedation[9]. This prospective multicenter 
trial is blinded to the data analyst and aims to recruit 
60 adult ICU patients requiring mechanical ventilation 
and sedation for at least 48 h, in which 40 patients will 
receive inhaled isoflurane and 20 patients will receive 
intravenous midazolam and/or propofol, titrated to a 
targeted Sedation Analgesia Score. Primary outcomes 
will assess adherence to the particular sedation protocol 
and atmospheric volatile concentration levels. Secondary 
outcomes that will be investigated include the quality 
of sedation, delirium, vasoactive drug support, time to 
extubation, serum fluoride levels, and mortality.
With an ever-rising concern for adverse events 
involved in our handling of patients, for any technique to 
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stand a chance of proving itself, all side-effects have to 
be clearly identified and communicated to the end users. 
In this sense, Purrucker et al[10] has issued a warning 
concerning the use of volatile anesthetic sedation in patients 
with a high risk of intracranial hypertension. Switching 
from Ⅳ sedation to sevoflurane decreased MAP and CPP 
in one-third of the patients studied to such an extent 
that the early termination of sevoflurane administration 
was required. The mechanism felt to be responsible was 
vasodilation in response to a decreasing MAP and a slightly 
raised partial-pressure carbon dioxide in patients with an 
already low baseline cerebral compliance.
In this paper, we want to warn about the use of 
volatile anesthetic sedation in a second subset of ICU 
patients, in particular those with EIR/EHS in need of 
intensive care. 
Although EIR/EHS is most often encountered in a 
military setting, the recent worldwide trend to organize 
mass (semi)marathons has resulted in a significant 
increase in the frequency of this problem in ICUs world-
wide. Indeed, the Centers for Disease Control and 
Prevention of the United States reported that EHI occurs 
both during practice and competition, with a disturbing 
trend of increasing incidence, and mentioning EIR/EHS as 
one of the leading causes of death in young athletes each 
year[11].
General anesthesia with volatile anesthetic agents, 
such as the currently used sevoflurane and desflurane, 
is known to potentially induce acute rhabdomyolysis in 
patients with a genetic predisposition to MH. Logically, 
the same risk is present when genetically MHS patients 
are exposed to volatile anesthetic sedation in the in-
tensive care setting. A recent publication reported on 
the development of MH in an ICU patient sedated with 
sevoflurane[12].
Other groups of patients are also at risk. A link 
between MHS and EIR has been suggested in the 
anesthesia literature for over two decades. The earlier 
reports linked MHS with EIR by demonstrating a 
positive in vitro contracture test. One of the larger series 
published[2] reports on the IVCT results in 12 unrelated 
patients with EIR. Ten of the 12 patients had IVCT 
results indicative of MHS. In the ensuing years, reports 
occurred providing evidence that “MH-mutations” in 
RYR1 were being associated with EIR. In 2002, Davis et 
al[13] reported two patients with EIR in which MHS was 
confirmed through in-vitro contracture testing and the 
presence of a RYR1 mutation.
Several similar cases were reported, and in 2013, 
Dlamini et al[14] published a large series of 39 unrelated 
families with rhabdomyolysis and/or exertional myalgia 
in which nine heterozygous mutations were found in 
14 families, several of them recurrent. Five of these 
mutations had previously been associated with MH. They 
conclude that RYR1 mutations account for a substantial 
proportion of patients presenting with unexplained rhab-
domyolysis and/or exertional myalgia, but also that 
various stressors (e.g., pain, environmental heat, viral 
infections, drugs) may need to be present to elicit acute 
rhabdomyolysis. They also suggest that “additional family 
studies are paramount in order to identify potentially MH 
susceptible relatives”. 
In a 2014 paper, Zhao et al[15] actually raised the 
question on whether the two disorders represent one 
and the same disorder, which they called the Human 
Stress Syndrome. This hypothesis has gained support, 
and MH and EIR/EHS are increasingly believed to be 
different presentations of the “expanding spectrum of 
RYR1-related myopathies”[16].
In view of the growing evidence that EIR in a 
substantial portion of the patients admitted to the ICU 
is a “non-anesthetic RYR1-related rhabdomyolysis”[16], 
it is of great importance for the patients and families 
involved to undergo a thorough investigation on the 
cause of the life-threatening rhabdomyolysis, certainly 
if the problem has been found to be recurrent. The 
following reasons substantiate this statement: (1) several 
“common” underlying causes with significant impact on 
patients’ lives have to be ruled out, such as sickle cell trait, 
CPTⅡ deficiency, McArdle’s disease (glycogen storage 
disease Ⅴ), myoadenylate deaminase deficiency, and 
others; (2) to identify potentially MHS individuals as 
implications for future general anesthesia are important. 
If a patient is found to be MHS, preventive measures 
concerning the anesthetic technique have to be taken. 
Over the last decade, several experts have stated 
that individuals who have a history of EHS should be 
screened for MHS[2,16-18]. Even though the IVCT is an 
invasive test, it is still considered to be the most sensitive 
and specific test to determine a patient’s predisposition 
to MHS. The estimation of the MH risk in a particular 
patient is certainly not straightforward, as illustrated by 
the case presentations. Patient 1 had a negative IVCT 
and a negative genetic analysis, and is considered to be 
non-MHS. Therefore, volatile anesthetics can safely be 
administered in the operating room/ICU to this patient. 
Patient 2 had a positive IVCT, but no mutation was found 
upon RYR1 sequencing. However, it is well known that 
a RYR1 mutation is found in only 50%-70% of patients 
with a positive IVCT[19]. CACNA1S cDNA sequencing was 
not performed in our patients in view of the cost and 
the large number of sequence changes reported, most 
of which are of unclear significance[20]. In this patient, 
volatile anesthesia has to be avoided in the future, 
because he is considered MHS by IVCT. Patient 3 had a 
positive IVCT and a positive RYR1 mutation (p.N2342S; 
c.7025A>G - exon 43) that was previously linked to 
MH, and therefore, this patient is clearly at risk for MH 
upon exposure to volatile anesthetic agents; and (3) If 
RYR1 mutations are found, the condition should be con-
sidered to be hereditary, and additional family studies are 
indicated.
The patient should be seen by a neurologist, because 
a large number of diverse etiologies have been implicated 
in acute EIR/EHS, and certain additional clinical features 
can aid to define the most appropriate investigations. 
A guideline for a diagnostic EIR/HS workup has been 
suggested by Capacchione et al[21]. Because of the rarity 
Heytens K et al . Heatstroke and volatile anesthetic sedation
26 February 4, 2017|Volume 6|Issue 1|WJCCM|www.wjgnet.com
and heterogeneity of these conditions, however, this EIR/
HS workup remains a real diagnostic challenge.
A third group of patients at risk when given volatile 
anesthetic sedation are patients with congenital myo-
pathies. This is a group of rare genetic muscle disorders (6 
in 100000 live births) characterized by different structural 
abnormalities in skeletal muscle fibers either observable 
by light- or EM microscopy, and symptoms of hypotonia 
and muscle weakness present at birth (although the 
clinical expression may be delayed until childhood or 
even adult life). These myopathies are genetically hetero-
geneous, but a substantial subgroup is linked with “gain-
of-function” mutations in the RYR1-gene, resulting in 
increased calcium conductance of the calcium-release 
channel and the potential for acute rhabdomyolysis when 
exposed to volatile anesthetics. This has been shown 
to be the case for central core disease, multiminicore 
disease, centronuclear myopathy, congenital fiber type 
disproportion, late-onset axial myopathy, and King-
Denborough syndrome[22].
The propensity of patients with muscular dystrophies 
(especially Duchenne muscular dystrophy) to react 
adversely to volatile anesthetic sedation is well known; 
however, this does not occur through the presence of 
RYR1 mutations but rather is the result of “toxic effects” 
of these agents as well as succinylcholine on the fragile 
sarcolemma. Prolonged exposure to volatile anesthetic 
agents, and certainly the use of succinylcholine, has to 
be avoided in this group of patients.
If intensive care sedation is needed in these patients, 
a combination of propofol, benzodiazepines, morphino-
mimetics, neuraxial block, and, as last resort, non-depolarizing 
neuromuscular blockers can be used. Dexmedetomidine 
use for procedural sedation is safe.
CONCLUSION
Dominantly inherited MHS is rare. Therefore, in the 
general population, life-threatening acute rhabdomyolysis 
following exposure to volatile anesthetics either in 
the operating room or the ICU is seldom encountered. 
However, because a substantial proportion of patients 
with EIR/EHS and congenital myopathies harbor RYR1 
mutations resulting in an increased calcium-conductivity 
of the Ca-release channel of the SR, volatile anesthetic 
sedation should not be used in these high-risk patients.
Contraindications for volatile anesthetic sedation in 
intensive care consist of: (1) known susceptibility for 
MH; (2) congenital myopathies (central core disease, 
multiminicore disease, centronuclear myopathy, congenital 
fiber type disproportion, late-onset axial myopathy, and 
King-Denborough syndrome); (3) duchenne muscular 
dystrophy; (4) exertional rhabdomyolysis; and (5) intra-
cranial hypertension.
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